Compare Biocon Ltd with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs PROCTER & GAMBLE HEALTH - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON PROCTER & GAMBLE HEALTH BIOCON /
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 22.5 53.2 42.3% View Chart
P/BV x 3.0 4.6 64.4% View Chart
Dividend Yield % 0.4 10.3 3.8%  

Financials

 BIOCON    PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    BIOCON
Mar-18
PROCTER & GAMBLE HEALTH
Dec-18
BIOCON /
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs1,1883,549 33.5%   
Low Rs3051,301 23.4%   
Sales per share (Unadj.) Rs68.7511.4 13.4%  
Earnings per share (Unadj.) Rs7.661.3 12.3%  
Cash flow per share (Unadj.) Rs14.074.0 18.9%  
Dividends per share (Unadj.) Rs1.00440.00 0.2%  
Dividend yield (eoy) %0.118.1 0.7%  
Book value per share (Unadj.) Rs86.3927.8 9.3%  
Shares outstanding (eoy) m600.0016.60 3,614.5%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.94.7 229.1%   
Avg P/E ratio x98.939.6 249.8%  
P/CF ratio (eoy) x53.432.8 163.1%  
Price / Book Value ratio x8.62.6 330.7%  
Dividend payout %13.2717.9 1.8%   
Avg Mkt Cap Rs m447,90040,257 1,112.6%   
No. of employees `0006.11.1 542.2%   
Total wages/salary Rs m9,3111,313 709.3%   
Avg. sales/employee Rs Th6,705.87,486.7 89.6%   
Avg. wages/employee Rs Th1,514.21,157.6 130.8%   
Avg. net profit/employee Rs Th736.9897.2 82.1%   
INCOME DATA
Net Sales Rs m41,2348,490 485.7%  
Other income Rs m2,062244 845.4%   
Total revenues Rs m43,2968,734 495.7%   
Gross profit Rs m8,2911,482 559.6%  
Depreciation Rs m3,851211 1,823.4%   
Interest Rs m6150-   
Profit before tax Rs m5,8871,514 388.8%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m1,569563 278.9%   
Profit after tax Rs m4,5311,017 445.4%  
Gross profit margin %20.117.5 115.2%  
Effective tax rate %26.737.1 71.7%   
Net profit margin %11.012.0 91.7%  
BALANCE SHEET DATA
Current assets Rs m41,48615,343 270.4%   
Current liabilities Rs m21,4131,960 1,092.4%   
Net working cap to sales %48.7157.6 30.9%  
Current ratio x1.97.8 24.8%  
Inventory Days Days6449 131.2%  
Debtors Days Days9428 331.0%  
Net fixed assets Rs m50,6611,209 4,189.3%   
Share capital Rs m3,000166 1,807.2%   
"Free" reserves Rs m48,80815,235 320.4%   
Net worth Rs m51,80815,401 336.4%   
Long term debt Rs m17,8980-   
Total assets Rs m99,89717,595 567.8%  
Interest coverage x10.6NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.40.5 85.5%   
Return on assets %5.25.8 89.1%  
Return on equity %8.76.6 132.4%  
Return on capital %9.610.3 93.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,0581,636 736.9%   
Fx outflow Rs m7,3484,368 168.2%   
Net fx Rs m4,710-2,732 -172.4%   
CASH FLOW
From Operations Rs m6,621-1,304 -507.8%  
From Investments Rs m-6,84012,697 -53.9%  
From Financial Activity Rs m-2,397-301 797.7%  
Net Cashflow Rs m-2,61211,093 -23.5%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 51.8 39.8%  
Indian inst/Mut Fund % 8.4 18.2 46.2%  
FIIs % 10.7 1.0 1,070.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 29.1 68.4%  
Shareholders   109,995 28,591 384.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Nov 15, 2019 (Close)

TRACK BIOCON

BIOCON - WYETH LTD COMPARISON

COMPARE BIOCON WITH

MARKET STATS